The current peripherally administered AONs in DMD do not cross the blood-brain barrier, but systemically delivered AONs with improved CNS penetration are under development,26,89 which could potentially enable dystrophin restoration in muscle and CNS from the same systemically administered therapy. Here, DMD is linked to Duchenne muscular dystrophy.